NVGN - Novogen Limited

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Novogen Limited

20 George Street
Level 5
Hornsby, NSW 2077
61 2 9472 4100

IndustryDrug Manufacturers - Major
Full Time Employees

Key Executives

Dr. James Garner M.A., MBA, MBBS, B.Sc (Hons), SAFin.CEO, MD & Exec. Director447.87kN/A44
Ms. Gabrielle Heaton BBUS (ACC), CPADirector of Fin. & Admin.48.57kN/AN/A
Dr. Peng Leong MBA, Ph.D.Chief Bus. Officer347.49kN/AN/A
Dr. Gordon Hirsch MBA, MBBCh, FCP(SA), BSc HonsChief Medical Officer204.63kN/AN/A
Ms. Catherine Hill ACA, GAICD, BSc (Hons)Company Sec.89.7kN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novogen Limited engages in the pharmaceutical research and development business in Australia. The company primarily has two drug technology platforms, which include superbenzopyran (SBPs) and anti-tropomyosin (ATMs). Its SBP technology platform offers Cantrixil, an intra-cavity anti-cancer agent for the treatment of ovarian cancer, malignant ascites, and malignant pleural effusion; and Trilexium for the treatment of brain cancers, neuroblastoma, and melanoma. Its ATM technology platform provides Anisina that destructs cancer cells cytoskeleton. The company is also developing various programs in the areas of regenerative medicine, facioscapulohumeral muscular dystrophy, and lysosomal storage disorder. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Corporate Governance

Novogen Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.